Category Archives: Stem Cell Doctors

IMAC (IMAC) Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of…

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

Read the original here:
IMAC (IMAC) Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of...

Croydon mum’s urgent appeal for stem cell donors who could save her two-year-old daughter – My London

People who meet two-year-old Shahera Khan adore her.

The young girl is described as wonderful, funny and calm.

Sadly, however, her life is not that of a normal girl her age. Shahera, who lives in Croydon with her mum, dad and five-year-old brother, suffers with a very rare immunodeficiency disease.

Its a fault in her immune system and means Shahera is unable to produce enough white blood cells, making her susceptible to infections. A worst case scenario would be she sustains a serious bacterial infection which could prove fatal.

For more news and features about London directly to your inbox sign up to our newsletter here

"Shahera is currently taking medication to protect her against serious bacterial infections and she has immunoglobulin transfusions every week," said her mum, Amina.

"At the moment she is doing okay but shes getting side effects from the medication."

Shaheras family have been told a stem cell transplant is her best chance of leading a normal life. Doctors will give her new, healthy stem cells via the bloodstream, where they begin to grow and create healthy red blood cells, white blood cells and platelets.

But Shahera needs a stem cell donor. Nobody in her family is a genetic match, so the family is working with blood cancer charity Anthony Nolan to raise awareness of the stem cell donor register.

The search is made more difficult due to her Bangladeshi heritage. Data shows patients like Shahera, from a black, Asian and minority ethnic background, have a 20 per cent chance of finding the best possible stem cell donor match, compared to 69 per cent for people with white, European heritage.

Amina said: "We need to find Shahera a donor as soon as possible.

"We want to raise awareness in the Asian, and particularly Bangladeshi community so people come forward - not only to help Shahera but for anyone who needs a donor.

"Its shocking that there is no match for Shahera and other people from Asian communities.

"With Shaheras condition the doctors would like to do the transplant as soon as possible. Theyve given us a couple of months to find a donor and suggested spring or summer next year for the transplant."

Shahera has regular appointments at Great Ormond Street Hospital and waiting for a stem cell donor is a "nerve wracking" process, Amina admitted.

"Shahera is wonderful. She touches everybody she meets; from family and friends to the people she meets in the hospital," Amina said.

"Shes very calm and everyone just loves her, shes funny too. To look at her, you wouldnt believe she was ill but what is going on inside is a totally different story.

"We dont want her to miss out on anything. She should be starting nursery this September, but we dont know what will happen because of her treatment.

"Were a happy family unit. My husband and I both work and we slot Shaheras appointments in around family life.

"Its nerve wrecking and upsetting, waiting to find a donor. It feels like a long process. Its not easy, we have our bad days as well as good days, but all we can do is look forward, and do everything we can to find Shahera a donor."

So far no match has been found but the family are hoping blood cancer charity Anthony Nolan can help raise awareness of the stem cell donor register.

Sarah Rogers, register development manager at Anthony Nolan, said: "Little Shahera wants to go to nursery, learn and make more friends just like other toddlers across the UK. For this to happen she needs a stranger to donate their stem cells.

"If youre aged 16-30 you can join the register online and well send you a cheek swab in the post.

"If youre found to be a match for a patient, you could donate your stem cells and give hope to families like Shaheras. Your support could help us give a patient, their family and their friends a second chance of life."

People aged 16-30 who are in good general health can find out more, and join the Anthony Nolan register at http://www.anthonynolan.org/saveourshahera.

Get more news updates for your local area by putting your postcode into our handy widget below:

Want more news? Go to our homepage.

Do you have a story? Email mylondonnewsdesk@reachplc.com.

Read more:
Croydon mum's urgent appeal for stem cell donors who could save her two-year-old daughter - My London

Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 – Yahoo…

- University of California Irvine is the first California site participating in Celularity's CYNK-001-COVID-19 clinical trial NCT04365101 using Celularity's investigational immunotherapy to treat adults who tested COVID-19 positive in underserved and disproportionately affected populations.

- CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells.

FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ --Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK) cells (CYNK-001) for the treatment of adults with COVID-19.The University of California Irvine is the first CA site to open for patient enrollment.

(PRNewsfoto/Celularity, Inc.)

CIRM's COVID-19 Project supports promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments or vaccines that utilize stem and/or progenitor cells. Celularity will use the CIRM grant to support the evaluation of the anti-viral activities of its cryopreserved investigational product, CYNK-001, in underserved and disproportionately affected populations with COVID-19, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Celularity received clearance from the United States Food and Drug Administration to proceed with a Phase I/II study to evaluate the safety, tolerability, and efficacy of CYNK-001 in patients with COVID-19.

"Our investigational product CYNK-001 showed great promise in preclinical studies, and we are optimistic that it will prove effective against corona virus diseases, including COVID-19. As part of our rapidly-scalable placental-derived cellular medicine platform, CYNK-001 could play an important role in the public health response to outbreaks of COVID-19 or other coronaviruses," said Robert J. Hariri, MD, PhD, Founder, Chairman and CEO of Celularity. "We are very grateful to CIRM for supporting our effort to make novel cellular medicines available to medically underserved and disproportionately affected persons in California."

Xiaokui Zhang, PhD, Chief Scientific Officer and Principal Investigator under the CIRM grant says "CYNK-001 has a range of biological activities that not only recognize and destroy virus-infected cells, but also coordinate a robust immune response that may lead to an effective and durable defense against the viral infection."

The trial will evaluate the safety and the clinical efficacy of CYNK-001 in SARS-CoV-2 positive subjects as measured by clearance of the SARS-CoV-2 and improvement in clinical symptoms or improvement in radiological evaluation of disease related chest x-ray. The primary objective of the Phase I portion of the study is to evaluate the safety, tolerability, and efficacy of multiple CYNK-001 intravenous (IV) infusions in COVID-19 patients and will be administered to up to 14 patients in three doses over the course of seven days.

The Phase II portion of the study is a randomized, open-label, multi-site study measuring multiple doses of CYNK-001 against a control group experiencing a similar degree of infection with best supportive care, with two co-primary endpoints. The first co-primary endpoint is to determine the virologic efficacy of CYNK-001 in facilitating the clearance of SARS-CoV-2 from mucosal specimens and/or peripheral blood. The second co-primary endpoint is to assess the impact of treatment with CYNK-001 on clinical symptoms among patients with COVID-19 related lower respiratory tract infection.

Story continues

Celularity has treated patients with severe COVID-19 and on ventilator support under compassionate use programs in U.S. CYNK-001 was well tolerated and may be associated with clinical benefit in selected cases.

About NK CellsNK cells are innate immune cells with an important role in early host response against various pathogens. Multiple NK cell receptors are involved in the recognition of infected cells. Studies in humans and mice have established that there is robust activation of NK cells during viral infection, regardless of the virus class, and that the depletion of NK cells aggravates viral pathogenesis.

About CYNK-001CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells. CYNK-001 is being investigated as a potential treatment option in adults with COVID-19, as well as for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. CYNK-001 cells derived from the placenta are currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and glioblastoma multiforme (GBM). On 1 April, the U.S. Food and Drug Administration cleared the Company's Investigational New Drug (IND) application for the use of CYNK-001 in adults with COVID-19.

About COVID-19The virus causing COVID-19 is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is a novel coronavirus that has not been previously identified. COVID-19 has become a global pandemic, with over 4.2 million confirmed cases in the USA and over 650,000 deaths reported to date worldwide.

About Celularity Celularity, headquartered in Florham Park, N.J., is a next-generation Biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics. Celularity's innovative approach to cell therapy harnesses the unique therapeutic potential locked within the cells of the post partum placenta. Through nature's immunotherapy engine the placenta Celularity is leading the next evolution of cellular medicine with placental-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com

Media Contact:

Name:Dani Frank

Email:celularity@factorypr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/celularity-announces-the-activation-of-first-california-clinical-trial-site-following-cirm-grant-award-to-advance-treatments-for-covid-19-301106515.html

SOURCE Celularity

More:
Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 - Yahoo...

‘Year of Preparations for the Next Fifty Years’ will contribute to countrys development process – Emirates 24|7

In 2020, the UAEs achievements, most notably the launch of the Hope Probe to Mars and the operation of Unit 1 of the Barakah Nuclear Power Plant, have proven that the "Year of Preparations for the Next Fifty Years" will significantly contribute to the countrys development process.

Despite the difficult circumstances facing the world caused by the coronavirus, COVID-19, pandemic, the UAE has succeeded in turning challenges into opportunities for innovation and development, which is reflected in its approach to limiting the spread of the virus through a range of creative measures, such as developing technology to discover the virus using lasers that generate results in a record time, using stem cell therapy for patients, and participating in global efforts to find a vaccine.

In 2020, the UAEs achievements reflect the national ambitions and wisdom of its leadership. The Hope Probe project involved nearly 200 Emirati engineers and researchers, who worked hard for six years to fulfil the UAE's dream to reach the Red Planet.

The Barakah Nuclear Power Plant also highlights the UAEs efforts to build the capacities of national cadres in this sector. Nearly 244 employees work for the Federal Authority for Nuclear Regulation, FANR, with 67 percent being Emiratis, of which 45 percent are in leading and managerial positions. Women also account for over 40 percent of the Authoritys employees.

Once all four units of the plant are commercially operating, the UAE's Barakah Nuclear Energy Plant will produce up to 25 percent of the country's electricity requirements while in parallel preventing the release of 21 million tons of carbon emissions each year.

On the level of combating COVID-19, Emirati national cadres and institutions joined the front line since the first day to discover the first case in the country, and contributed to achieving milestones at the global level.

In May, a patent was granted by the Ministry of Economy for the development of an innovative and promising treatment for COVID-19 infections using stem cells. The treatment was developed by a team of doctors and researchers at the Abu Dhabi Stem Cell Center, ADSCC, and involves extracting stem cells from the patients own blood and reintroducing them after activating them.

QuantLase Imaging Lab, the medical-research arm of the Abu Dhabi Stock Exchange-listed International Holdings Company, IHC, announced that it has developed novel equipment which enables for much faster mass screenings, with test results available in seconds and allowing testing on a wider scale.

The technology will reinforce the UAEs position as a hub of research and innovation, as scientists around the world scramble to devise a faster method of testing for patients suspected to have been infected with the coronavirus and potentially identifying carriers before they become infectious.

The first World Health Organisation, WHO, enlisted global clinical Phase III trial of Sinopharm CNBGs inactivated vaccine to combat COVID-19 started in Abu Dhabi.

The worlds first Phase III trial is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare, currently at the forefront of the battle against COVID-19 in the UAE, and Sinopharm CNBG, the worlds sixth-largest vaccine manufacturer, ranked 169th on the Fortune Global 500 list of 2018.

The trials are being operated by health practitioners from Abu Dhabi Health Services, SEHA, who are providing facilities at five of their clinics in Abu Dhabi and Al Ain in addition to a mobile clinic to ensure the trials are readily accessible to volunteers participating in the programme.

Follow Emirates 24|7 on Google News.

Print Email Facebook LinkedIn Whats App Pin Interest

Read the original:
'Year of Preparations for the Next Fifty Years' will contribute to countrys development process - Emirates 24|7

Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody – – pharmaphorum

Incyte and Morphosys Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumbersome CAR-T therapy.

At the beginning of the year Incyte paid $750m to Morphosys for the CD-19 targeting antibody, which has been approved in combination with BMS Revlimid (lenalidomide) for adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified.

The indication also covers DLBCL arising from low grade lymphoma and patients not eligible for autologous stem cell transplant.

Monjuvi (tafasitamab) targets the CD-19, a protein on the surface of B-cells that is also targeted by Amgens bispecific antibody Blincyto (blinatumomab) for acute lymphoblastic leukaemia (ALL), as well as two CAR-T therapies Novartis Kymriah (tisagenlecleucel) and Gileads Yescarta (axicabtagene ciloleucel) that are already approved for DLBCL and other B-cell cancers.

Under the agreement with Morphosys the companies will co-market the drugs in the US, while Incyte has exclusive rights outside the US.

The deal with Morphosys could see Incyte pay up to $1.1 billion should certain targets be achieved.

Xencor, which developed the drug before licensing it to Morphosys in 2010, will receive a $25 million milestone payment and a royalty on worldwide net sales.

Before any rebates or discounts Monjuvis wholesale price will average $16,500 per month in the first year of therapy, followed by an average of $13,000 per month in subsequent years because of a decrease in the required number of doses per cycle.

At around $198,000 for the first year this is pricey but may work out as less expensive than CAR-Ts from Novartis and Gilead, depending on how long patients stay on treatment.

CAR-Ts cost $373,000 in adult DLBCL for a single shot of the cell therapy.

CAR-Ts can be highly effective, producing a complete response in about a third of patients, but are made by harvesting a patients own cells and modifying them to fight cancer a lengthy process that might not appeal to all patients.

There are also dangerous side-effects with CAR-Ts, where doctors often have to manage cytokine storms where the immune system goes into overdrive and begins to attack a patients own body.

The FDA approval of Monjuvi was based on data from the MorphoSys-sponsored phase 2 L-MIND study, an open label, multicentre, single arm trial of Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL.

Results from the study showed an overall response rate of 55%, including a complete response rate of 37% and a partial response rate of 18%.

Warnings and precautions for Monjuvi included infusion-related reactions, serious or severe myelosuppression (including neutropenia (50%), thrombocytopenia (18%), and anemia (7%)), infections (73%) and embryo-foetal toxicity. Neutropenia led to treatment discontinuation in 3.7% of patients.

This accelerated approval may depend on further confirmatory data from larger trials.

Updated to include pricing information

See original here:
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody - - pharmaphorum

Crowdfunding to the rescue for this cancer patient – Telangana Today

New Delhi: Cancer takes innumerable lives each year, and so does the unavailability of cancer treatment due to lack of funds. 33-year-old Nushafreen Palsetia, a software engineer based in Mumbai, was recently diagnosed with a very aggressive form of cancer. Despite a relapse, what helped was life-saving support pouring from over 1,700 donors.

Nushafreen was first diagnosed with Non-Hodgkin Lymphoma in April 2019. After a year of enduring aggressive treatment, she tried to get back to her normal life and work. Unfortunately, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), cancer relapsed in her liver in May 2020 which was an unexpected major shock, leaving her and all of her family overwhelmed.

Doctors planned to perform an autologous (her own stem cells) bone marrow transplant in India after the chemotherapy but further tests showed involvement of the bone marrow as well. Hence, her treating doctor recommended the modern CAR-T Cell therapy treatment, available only in the USA, UK, Israel, and a few European countries.

Nushafreens family found Israel as the most affordable option as compared to all other countries offering the treatment. They reached out to Sheba Medical Centre in Israel which estimated the medical expenses as 200,000 USD (approximately Rs 1.5 crore). The treatment will require Nushafreen to be hospitalized for a month or more for the response to treatment and immediate follow up.

As Nushafreens family couldnt afford the high medical expenses, an ImpactGuru crowdfunding campaign was initiated. In two weeks, Nushafreens ImpactGuru.com Page has raised over Rs 1 crore from 1750 donors. The platform raises money online for medical expenses via crowdfunding such as cancer, transplants, and accidents.

According to the co-founder and CEO of the healthcare crowdfunding platform, Piyush Jain, Crowdfunding is driven by a culture of generosity, it allows people to raise money quickly in a hassle free manner without any payback liability. This is a new record for our platform with a single patients family being able to raise more than Rs 1 crore. We hope Nushafreen recovers soon and more patients come forward to utilize our platform in their time of need to get the best available treatment for critical illnesses.

Read more here:
Crowdfunding to the rescue for this cancer patient - Telangana Today

Global Multiple Myeloma Treatment Market-Industry Analysis and forecast 2019 2027: By Application, Type, and Region. – Red & Black Student…

Global Multiple Myeloma Treatment Market size was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 11.34% from 2019 to 2027, reaching nearly US$ XX Mn.

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Multiple myeloma, also known as Kahlers disease, is a type of blood cancer of plasma cells that are found in the bone marrow. Multiple myeloma causes cancer cells to accrue in the bone marrow, where they attack the strong blood cells.

Multiple myeloma treatments have developed significantly above the last decade. New multiple myeloma treatments have provided efficient survival rates between myeloma patients. It has been also observed that the future drug pipeline of multiple myeloma is promising, biological drugs and stem cell-based therapies are likely to fuel the multiple myeloma treatment market in the upcoming years. On the other hand, the costs of radiotherapeutic equipment implementation, a limited number of target patients population, strict legal regulations are expected to hamper the market growth. Likewise, the MMR report contains a detailed study of factors that will drive and restrain the growth of the multiple myeloma treatment market globally.

Multiple Myeloma accounts for approximately 2.5% of the cancer-related deaths globally and is the second most major type of blood cancer next to Hodgkins Lymphoma. According to the World Cancer Research Fund, in 2018, above 159500 cases of multiple myeloma were diagnosed with the condition, where the occurrence rate among women and men was found in the ratio 1.2:1. The onset of the disease occurs after the age of 60. In recent times, the age of onset is drastically decreasing. In the year 2001, only two medications were available for treating multiple myeloma but now in 2020, 18 medicines are available. Moreover, there are over 25 FDA-approved drugs for treating multiple myeloma with therapeutics such as pomalidomide, carfilzomib, panobinostat, and ixazomib. The availability of new medications has given new hope for better treatments and better results and thus affecting the growth of the market as well. However, the survival of patients with a limited response while receiving treatment with primary immunodeficiency therapy remains poor and is one of the major challenges.

The MMR report covers the segments in the multiple myeloma treatment market such as type and application. By application, the hospital is expected to continue to hold the largest XX.85% share in multiple myeloma treatments market thanks to growing specialist doctors providing the best chance of long term survival.

North Americas multiple myeloma treatments market was valued at US$ XX.26 Mn. in 2019 and is expected to reach a value of US$ XX.13 Mn. by 2027, with a CAGR of 9.3%. The number of patients in the U.S is growing YoY with nearly 14600 new cases diagnosed annually. In 2017 alone there were approximately 142000 patients diagnosed for multiple myeloma.

Europe and the South African population are prone to develop multiple myeloma when compared with Asian economies. Though, the population in the APAC region outwits Europe and Africa. Further, growing the adoption rate of novel therapies, coupled with the support from the government along with non-government organizations and improving the survival of multiple myeloma patients.

The research study includes the profiles of leading players operating in the global multiple myeloma treatment market. Eli Lilly Company acquired ARMO Biosciences to develop immunotherapies for the treatment of cancer, hypercholesterolemia, inflammatory, and fibrosis diseases.

The objective of the report is to present a comprehensive analysis of the Global Multiple Myeloma Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Multiple Myeloma Treatment Market dynamics, structure by analyzing the market segments and projects the Global Multiple Myeloma Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Multiple Myeloma Treatment Market make the report investors guide. Scope of the Global Multiple Myeloma Treatment Market

Global Multiple Myeloma Treatment Market, by Applications

Hospitals Clinics Cancer Treatment and Rehabilitation Centers Global Multiple Myeloma Treatment Market, by Type

Proteasome Inhibitors Immunomodulatory Agents (IMiDs) Histone Deacetylase (HDAC) Inhibitors Immunotherapy Cytotoxic Chemotherapy Global Multiple Myeloma Treatment Market, by Region

Asia Pacific North America Europe South America Middle East & Africa Key players operating in Global Multiple Myeloma Treatment Market

Celgene Corporation Janssen Biotech, Inc. Bristol-Myers Squibb Company Novartis AG Cellectar Biosciences Inc. Millennium Pharmaceuticals Amgen, Inc. bbVie Genzyme Corporation Juno Therapeutics Eli Lilly and Company Glenmark Pharma

Global Multiple Myeloma Treatment Market Request For View Sample Report Page : @ https://www.maximizemarketresearch.com/request-sample/65671 About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info: Name: Vikas Godage Organization: MAXIMIZE MARKET RESEARCH PVT. LTD. Email: sales@maximizemarketresearch.com Contact: +919607065656 / +919607195908 Website:www.maximizemarketresearch.com

The rest is here:
Global Multiple Myeloma Treatment Market-Industry Analysis and forecast 2019 2027: By Application, Type, and Region. - Red & Black Student...

stem cell doctor – regenexx.com

This past year or so I have lectured at many conferences and taught a few courses on the orthopedic use of stem cells. What I have seen and experienced concerns me greatly. With the explosion in stem cell use this past year, the number of people doing it well has become a smaller and smaller percentage of the total physicians offering the treatment.

First, why is this happening? The race by physicians to adopt stem cells has created a weird educational problem. Physicians that have full practices dont have a lot of time for education and the companies that sell automated centrifuges or kits to concentrate stem cells have financial incentives to sell as many as possible. Put these together and you get what we see doctors who dont have the base training to do this type of work, who arepoorly trained.

I can break these stem cell doctors down into a few different categories:

1. I have no clue how to use guidance-These physicians include many orthopedic surgeons and family doctors. For example, they know that injecting stem cells into the knee joint accurately is important, but they refuse to use imaging guidance to ensure theyre in the joint. For some, like many orthopedic surgeons its arrogance. They believe thatdespite scientific studies to the contrary, they can accurately access the joint. Other times, its just unwillingness to climb the steep educational mountain of learning ultrasound or fluoroscopy and purchase expensive new equipment.

2. I took a weekend course so now I can advertise that Im a stem cell expert-There is a saying, dont know what they dont know that accurately describes this group. Simple but critical details have been left out of their training. For example, the fact that certain common anesthetics will kill stem cells dead. Or that taking stem cells from only one bone marrow site virtually assures that the total number of stem cells will be less than when multiple sites are drawn.

3. This is a heck of a business opportunity-This group is made up of physicians who are more businessmen than doctors. Theysimply dont care if these procedures are being done right or wrong, only that the public sees a slick web-site and anyone who has a credit card is a candidate. They see dollar signs and anything that reduces the bottom line (like extensive training) isnt a good thing.

4. I have no idea what Im injecting, but some sales rep told me it was stem cells-These doctors have very little knowledge about stem cells and unlike the doctors above, wont be bothered to have to buy new equipment or take a course. They simply want something that sits on the shelf that they can inject when somebody with the cash comes by that wants a stem cell injection. In this case an attractive sales rep came to the office and told them that an expensive little vial contained amniotic stem cells. They took the bait hook, line, and sinker never questioning as we did whether what the sales rep claimed was accurate or simply just a tale told to sell product. Regrettably the vial of amniotic stem cells sitting in the freezer doesnt contain any living cells, let alone stem cells.

5. I only kind of know what Im injecting-These clinics tend to use bedside centrifuges and have no ability to count the dose of whats being injected, hence they really have no idea if the stem cell draw was adequate or if they have many or few cells. All this is obviously critical for delivering high quality care.

6. I only kinda know where Im injecting-These doctors use guidance (unlike the category described as #1 above), but they only use it at the most basic level of competency. So for example, if your ACL ligament in the knee needs stem cells, they would have no idea how to get stem cells to that specific spot, simply how to generally get them inside the knee joint which wont help your ACL much.

What can you do as a patient to protect yourself as a patient considering orthopedic stem cell therapies? Here are questions to ask your doctor:

1. Do you use imaging guidance to take, and place, cells? If no, then find a provider that does.

2. How many hours of stem cell specific training have you had? How many patients have you treated with stem cells? Be a bit careful here, as the staff wont know the answer to these questions and the doctor will often give evasive answers. In addition, many doctors will often substitute their experience with platelet rich plasma when they answer the stem cell experience question to make it look like they have more experience than they actually have.

3. Be wary of any clinic that claims they areinjecting amniotic stem cells. There is no commercial product that we have tested that contains any viable stem cells and if the doctor is claiming or suggesting that he or she is doing this their knowledge of stem cells only extends to what thesales rep told them to push product never a good thing.

4. Ask if the doctor has the ability to count the cells that come out of his machine. Ask to see those exact counts. If they cant do this run

5. Make sure that the stem cell doctor has advanced interventional skills i.e. has the ability to precisely place the cells where theyre needed. Heres a question to ask -How many different structures in the knee can your doctor inject under guidance and can you name them?. The answer for a high level and sophisticated provider would be: intra-articular, patellar and quadriceps tendons, patello-femoral joints, ACL, PCL, MCL, LCL, pes anserine tendons, medial meniscus, lateral meniscus, etc If what you hear is that the doctor puts them inside the knee and they know where to go, run

The upshot? At Regenexx we hand pick doctors who have certain skills and this makes them a 1 in 100 doctor . We then train and support these doctors extensively. The good news for our patients is that they can access physicians all over the country that are highly skilled, the bad news for the average patient who doesnt do his or her homework is that the likelihood of randomly finding one of those highly skilled doctors is getting lower and lower every year!

Read more:
stem cell doctor - regenexx.com

Former SEC Head Coach, AD Hospitalized With COVID-19 – The Spun

Late Friday night, Alabama athletic director Greg Byrne shared a statement from former Alabama AD Bill Battle.

In the statement, Battle revealed he has been hospitalized with COVID-19. The former Tennessee Volunteers head coach said doctors expect him to make a full recovery.

I appreciate the prayers and well-wishes from so many, and want to let you know that Im stable and resting comfortably, he said. Ive got great doctors and nurses at UAB looking after me and expect to make a full recovery. Time and patience are important in the meantime.

Byrne took over for Battle as the Crimson Tides athletic director after Battle retired. Battle served as Alabamas athletic director from 2013-17.

Continued thoughts and prayers for Coach Battle for a full recovery. pic.twitter.com/bfXyNoDQRI

Greg Byrne (@Greg_Byrne) August 1, 2020

The 78-year-old began battling a form of cancer in 2014 and had stem cell transplants in 2016. Despite battling through the cancer treatments, he remained on the job as Alabamas athletic director.

Battle played his college football at Alabama, where he played under head coach Bear Bryant. He eventually got into coaching and served as an assistant at Army and Tennessee.

Battle took over as the head coach of the Volunteers in 1970 and led the team to an 11-1 record. In seven seasons as the head coach at Tennessee, he racked up a 59-22-2 record. He led the team to five bowl games, going 4-1 in those games.

We hope the former coach and AD has a speedy recovery.

Andrew McCarty is a writer for The Spun.

Here is the original post:
Former SEC Head Coach, AD Hospitalized With COVID-19 - The Spun

Think You Might Have NMOSD? Diagnosis May Take a While – HealthCentral.com

If youre suddenly experiencing blurred vision, numb limbs, relentless vomiting, or hiccups that last for days on end, you probablyno, you definitelywant to know whats going on, stat. But getting an accurate diagnosis for these unsettling symptoms isn't always straight forward. While theyre the classic signs of the autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), they can ring true for other conditions, too. So, it may take some sleuthing work before your doctor can put all the pieces together and get you on the right treatment path. Heres why:

NMOSD, a.k.a. Devics disease, accounts for just 2% of all demyelinating diseasesthose that damage the myelin sheath, the protective covering on your nervesso theres a good chance your primary care physician has never had a single patient with the disease. NMOSD attacks myelin on the optic nerve (which carries visual info from the eyes to the brain), the spinal cord, and sometimes the brainstem, leading to a wide range of symptoms that affect vision, balance, and even bladder and bowel function.

Symptoms develop over a period of a few days and peak within a week to 10 days, says Elias Sotirchos, M.D., director of the Neuromyelitis Optica Clinic at Johns Hopkins University in Baltimore. But if you were to google your symptoms (and we suspect you already have), youll see that theres a lot of overlap with other conditions including multiple sclerosis (MS), lupus, and even a brain tumor. So, before your doc lands on an NMOSD diagnosis, he may considerand potentially try to rule outthese other, more common issues first.

If you have blurry vision and throbbing eye painwhich can happen because NMOSD often causes a condition called optic neuritis (ON), leading to inflammation of the optic nerveyoud expect your doc to find some evidence of it when looking into your eyes during a regular eye exam. But with NMOSD, thats not always the case.

Optic disc swelling may not be present, says Dr. Sotirchos. Getting an ON diagnosis, then, comes from other parts of of an eye exam, a thorough patient history, and an optical coherence tomography (OCT) scan. This non-invasive diagnostic test can help spot swelling and damage of nerves in the back of the eye, and can also help nail an ON diagnosis, he adds. An MRI can also be done to ID which part of the nerve is involved.

ON happens in about half of all MS cases. About 20% of the time, its one of the first symptoms of that condition, according to research published in the journal Eye and Brain. So, if you go to your doctor with sudden vision loss or pain behind one or both eyes, your doctor may initially suspect MS.

And to confuse matters more, NMOSD was once considered a variant of MS, not a completely separate disease. Up until about 15 years ago, if a patient came in with [these symptoms], they would be diagnosed with MS, says Patricia Coyle, M.D., interim chair of the department of neurology at Stony Brook University in Stony Brook, NY.

Waking up to one or both limbs feeling weak, numb, or even paralyzed can be pretty scary. Or maybe you cant control your bladder, or urinate at all. These are things that can happen with you have transverse myelitis (TM). TM is diagnosed through a medical history and a neurological exam, as well as an MRI to look for spinal cord lesions that are typical with TM.

But your physician isnt finished there. He has to figure out why you have it. TM can signal NMOSD or MS, but it can also stem from other autoimmune disorders, vascular causes, and infections, as well as compression from a mass or even unexplained injury. So these other possibilities may need to be consideredand then rejectedbefore NMOSD emerges as the likely cause of your TM symptoms.

If your brainstem is the target of an NMOSD attacka rare occurrence in an already rare diseaseyour symptoms, while intense, may not immediately point to this condition.

NMOSD brainstem attacks arent as common as ON and TM. They happen in just 10% of cases. Nausea and vomiting might be dismissed as the flu or even food poisoning. Its only after youve been throwing up for daysor even weeksthat your doctor may start looking for other causes.

Hiccups are usually benign and can be triggered from carbonated beverages, alcohol, stress, eating too much, or swallowing air. But when they linger for more than 48 hours, your doctor may suspect nerve damage or irritation caused by reflux or even a cyst or tumor, central nervous system conditions including MS and stroke, as well as metabolic diseases (such as diabetes and kidney disease) before determining theyre actually the result of an NMOSD attack.

Fortunately, there are some highly specific blood tests that can tell docs if you have NMOSD. Back in 2004, researchers discovered that about 75% of people with NMOSD have antibodies in their blood called aquaporin-4 antibodies (AQP4-IgG). These antibodies target water channels (aquaporins) located on astrocytes, a type of cell in the central nervous system. We now realize that NMOSD is [usually] an immune attack on aquaporin-4, says Dr. Coyle.

About 20% of people with NMOSD dont have AQP4-IgG, but they may have another kind of antibody: myelin oligodendrocyte glycoprotein (MOG-IgG), a protein in the outer layer of the myelin sheath. Identifying these two antibodies have helped docs get to an NMOSD diagnosis faster than before (and rule out MS in one fell swoop).

Even so, getting your results can take weeks, leaving you, well, a bundle of nerves. And a small percentage of people with NMOSD wont have either antibody, even though they have all the classic NMOSD symptoms. If this happens to you, after your bloodwork comes back your doctor may schedule more tests, including a spinal tap and an MRI.

There is some association between NMOSD and the autoimmune disorder lupus. Some people with NMOSD will test positive for antibodies associated with lupus, even if they dont have any signs of that condition, says Dr. Sotrichos. The overlap between NMO and lupus likely has to do with a shared genetic tendency to developing these two autoimmune diseases, he says.

Interestingly, those who do have lupus and symptoms of ON and TM often carry AQP4-1gG antibodiesas many as 60%, suggests a study in Lupus. People with lupus with transverse myelitis, optic neuritis, or other neurological symptoms consistent with NMOSD should be tested for AQP4-IgG at that time, Dr. Sotirchos advises. In most cases, those who are positive for AQP4-IgG have actual signs of NMOSD, suggesting it may be co-existing with lupus.

As if this rare disease isnt complex enough, there are two types: relapsing, which is when you get repeated attacks with months or even years of remission in between, and monophasic, a single attack that lasts for at least a month or two. Your doctor wont know which one you have right away, but your bloodwork holds some clues: AQP4-IgG-positive NMOSD is typically treated as relapsing.

Those with MOG-IgG antibodies may have a monophasic attack, but its a wait-and-see game. If patients [with MOG-IgA antibodies] are followed long enough, the vast majority will have a relapse, says Dr. Sotirchos. So, doctors treat most cases as if they are the relapsing type.

Now that you have an official diagnosis of NMOSD, you might sigh with relief to finally have a name for what youve been experiencingeven as you battle worry, or even fear. Deep breath. Know that in the past few years powerful new treatment options have emerged to reduce the likelihood of another attack occurringto help keep you symptom-free in the future.

More here:
Think You Might Have NMOSD? Diagnosis May Take a While - HealthCentral.com